Controlling methicillin resistant Staphyloccocus aureus and Pseudomonas aeruginosa wound infections with a novel biomaterial.
Wound infections, especially those associated with methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa, offer considerable challenges for clinicians. Our laboratory has recently developed novel composite biomaterials (DRDC) for wound dressing applications, and demonstrated their in vitro bactericidal efficacy. In the present study, we assessed the proliferation of planktonic and sessile Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in porcine full-thickness wounds covered for up to 48 h with either saline- or mafenide acetate-loaded DRDC puffs and meshes. All biomaterials were applied 4 h following bacterial inoculation of the wounds with methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa, to allow colonization of the tissues and initiation of biofilm formation. The drug-loaded biomaterials eradicated both the planktonic and biofilm bacteria in the wounds within 24 h (p <. 05), irrespective of the bacterial strain or architecture of the dressing. While the wound bioburdens increased in the ensuing 24 h, they remained approximately 2 log(10) colony-forming units (CFU) below (p <. 05) their respective baseline values. Similarly, less than 4 log(10) CFU was recovered in the drug-loaded DRDC biomaterials throughout the study. These data show that the DRDC puffs and meshes are effective in delivering certain medications, such as antimicrobial agents, to the wound bed, suggesting considerable value of this material for treating wounds, especially those with irregular shapes, contours, and depths.
Martineau
Lucie
L
Defence Research & Development Canada, Valcartier, Québec, Quebec, Canada. lucie.martineau@drdc-rddc.gc.ca
Davis
Stephen C
SC
Peng
Henry T
HT
Hung
Andy
A
D000818:Animals; D000891:Anti-Infective Agents, Local / Q000627:therapeutic use*; D001458:Bandages; D001672:Biocompatible Materials / Q000627:therapeutic use*; D018441:Biofilms / Q000187:drug effects / Q000254:growth & development; D005260:Female; D008272:Mafenide / Q000627:therapeutic use*; D016106:Methicillin Resistance / Q000187:drug effects*; D011552:Pseudomonas Infections / Q000188:drug therapy; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000254:growth & development; D013203:Staphylococcal Infections / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development; D013234:Stem Cells / Q000187:drug effects; D013552:Swine; D014945:Wound Healing / Q000187:drug effects; D014946:Wound Infection / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control
D000891:Anti-Infective Agents, Local; D001672:Biocompatible Materials; D008272:Mafenide